Transcode Therapeutics, Inc. 8-K

What Happened

• On February 5, 2026, TransCode Therapeutics, Inc. (RNAZ) issued a press release announcing that, in collaboration with Quantum Leap Healthcare Collaborative, it submitted an Investigational New Drug (IND) application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead therapeutic candidate, TTX‑MC138. The press release is furnished as Exhibit 99.1 to the Form 8‑K filed the same day.

Key Details

• Date filed: February 5, 2026 (8‑K filing and press release).
• Program: IND amendment for a planned Phase 2a clinical trial of TTX‑MC138 (TransCode’s lead candidate).
• Partner: Collaboration with Quantum Leap Healthcare Collaborative.
• Exhibit: Press release provided as Exhibit 99.1 to the Form 8‑K.

Why It Matters

• Submission of an IND amendment is a formal regulatory step required to progress into a Phase 2a study; acceptance or clearance by the FDA would enable the company to begin the planned mid‑stage clinical trial. For investors, this represents advancement of TransCode’s lead program and continued clinical development activity, but it is a procedural milestone rather than evidence of clinical success or revenue impact. The filing signals ongoing R&D progress and partnership activity, which are material to the company’s development timeline.